[A17-37] Dolutegravir (HIV infection) - Addendum to commission A17-11
Last updated 21.09.2017
Commission awarded on 10.08.2017 by the Federal Joint Committee (G-BA).
Immune system and infections
HIV infection in children with antiretroviral pretreatment or in treatment-naive children
Added benefit still not proven: data from studies in adults not transferable to children
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.